Syngene
Syngene International is one of the leading India-based contract research organisations, offering a suite of integrated, end-to-end discovery, development and manufacturing services for novel molecular entities across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. [1]
 | |
| | |
| Type | Public / Private |
| Founded | 2000 |
| Headquarters | Bangalore, Karnataka |
| Number of employees | 1,001-5,000 |
Contents
About
Incorporated in 1993 as a subsidiary of Biocon Limited, Syngene is a leading custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. Our multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.
Our highly experienced scientific and project management teams ensure:
- Timely execution of projects
- Cost effectiveness and quality of the projects
- Confidentiality and protection of intellectual property
Syngene has state-of-the-art research facilities certified with ISO 9001:2008, ISO 14001:2004, and OHSAS 18001:2007. Our animal facilities are GLP certified by the Indian authorities and AAALAC accredited. Over the last 20 years, we have successfully offered these services to more than 290 clients including start-up companies, large pharma/ biotech, agrochemical, chemical, nutrition and animal health companies in the USA, Europe and Asia Pacific including Japan.
Syngene has a strong corporate governance framework with a focus on client satisfaction, quality, safety, ethics and integrity. Our ability to deliver significant value to our customers by leveraging our scientific skills, global mind set and India’s cost competiveness differentiates us as one of the most preferred partners.
Specialties
- Phase I-IV clinical Trials
- BA/BE & PK/PD studies
- Diabetology
- Oncology
- Rheumatology
- Infectious diseases
- Gastroenterology
- Nephrology
- Cardiology
- Neuropsychiatry
- Immunology
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 17, 2023 | Shashanktutu | @unseenvalue Hopefully the correct name of this child is Syngene |
| April 17, 2023 | EagleEyeReview | Important Intraday Levels for Next Session
Stock : #SYNGENE R3 :630.4 R2 :625.6 R1 :618.6 CLOSE :611.6 S1 :606.8 S2… https://t.co/86ZKpA7sO9 |
| April 17, 2023 | EagleEyeReview | Tchinical Analisys Update #17Apr2023 13:16
Stock : #SYNGENE 30 Min RSI :33.22 30 Min RSI Comment :Weak with Negativ… https://t.co/v3cEhcsN9b |
| April 17, 2023 | DhanLive | ↘️ Bearish: Syngene International is at day low. LTP at 610.60 on NSE. Thousands of bearish trends as they happen. See them live on Dhan. |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
References
https://www.linkedin.com/company-beta/220238/
http://www.syngeneintl.com/about-syngene/overview
Verification history
1,936 days ago- View all verifications
